WB result of GLI1 Recombinant Rabbit mAb
Primary antibody: GLI1 Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: RD whole cell lysate 20 µg
Lane 2: HepG2 whole cell lysate 20 µg
Lane 3: A673 whole cell lysate 20 µg
Low expression control: RD whole cell lysate; HepG2 whole cell lysate
Secondary antibody: Goat Anti-rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 118 kDa
Observed MW: 160 kDa
This blot was developed with high sensitivity substrate
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | GLI1 |
| Synonyms | Zinc finger protein GLI1; Glioma-associated oncogene; Oncogene GLI; GLI; GLI1 |
| Immunogen | Synthetic Peptide |
| Location | Cytoplasm, Nucleus |
| Accession | P08151 |
| Clone Number | S-2678-117 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | WB |
| Reactivity | Hu |
| Positive Sample | A673 |
| Purification | Protein A |
| Concentration | 1 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, -20 °C as supplied |
Dilution
| application | dilution | species |
| WB | 1:1000 | Hu |
Background
GLI1 (Glioma-associated oncogene homolog 1) is an 110 kDa zinc-finger transcription factor of the GLI family that acts as the primary activator of the Hedgehog (Hh) signaling pathway: in response to Hh ligands, smoothened-mediated inhibition of the Patched receptor is relieved, allowing GLI1 to accumulate in the nucleus where it binds GACCACCCA-like motifs to drive expression of target genes that regulate cell proliferation, stem-cell maintenance, differentiation, and tissue patterning during embryogenesis; in adults, tight control of GLI1 is essential because its dysregulation—through activating mutations, ligand overproduction, or loss of suppressors such as PTCH1 or SUFU—promotes oncogenic transcriptional programs implicated in basal-cell carcinoma, medulloblastoma, pancreatic, breast, and other cancers, making GLI1 both a biomarker of pathway activity and a therapeutic target for small-molecule inhibitors like vismodegib and arsenic trioxide.
Picture
Picture
Western Blot
